New drug trial targets recurrent brain tumors
NCT ID NCT06970145
Summary
This study is testing whether the drug anlotinib can help control recurrent craniopharyngioma, a type of brain tumor that has returned after previous surgery. The trial will enroll 57 adults to see if the drug shrinks tumors, delays tumor growth, and is safe to use. This is an early-phase study without a comparison group, focusing on gathering initial safety and effectiveness data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRANIOPHARYNGIOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Southern Medical University, Nanfang Hospital, Department of Neurosurgery
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.